RPRX250117C22500
- 7.87
- 0.000.00%
Royalty Pharma Newsroom
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
TD Cowen Initiates Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $42
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Royalty Pharma (RPRX) Gets a Buy From TD Cowen
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $39
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $39
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Morgan Stanley Keeps Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma Is Maintained at Buy by Citigroup
Royalty Pharma Analyst Ratings
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Royalty Pharma Analyst Ratings
Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51
Buy Rating Affirmed for Royalty Pharma Amidst Strong Financials and Positive Growth Outlook
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Royalty Pharma (RPRX)